Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

22 mai 2026 15h30 HE | Source: Pharming Group N.V.

European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union

Pharming announces the European Commission (EC) has granted Marketing Authorization for Joenja (leniolisib)
22 mai 2026 13h30 HE | Source: Novo Nordisk A/S

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)

CHMP has adopted a positive opinion, recommending marketing authorisation of Wegovy® 7.2 mg in a single-dose pen for people living with obesity.
21 mai 2026 14h50 HE | Source: ODDIFACT

ODDIFACT Receives European Commission Orphan Drug Designation for Infliximab in Kawasaki Disease

ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.
21 mai 2026 14h50 HE | Source: ODDIFACT

ODDIFACT obtient la désignation médicament orphelin de la Commission Européenne pour l’infliximab dans la maladie de Kawasaki

ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.
30 mars 2026 08h00 HE | Source: Teva Pharmaceutical Industries Ltd

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.Teva’s proposed biosimilar...
27 mars 2026 02h00 HE | Source: Pharming Group N.V.

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Pharming announces positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
22 déc. 2025 15h00 HE | Source: Vystar Corp.

Vystar® Reports, Following its First of its Kind Court Victory against EMA Financial, Inc. of $497,439.58 in Legal Fees and Costs Awarded.

Worcester, MA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vystar® Corporation (OTCQB: VYST) Vystar® is proud to report; Following its first of its kind court victory on behalf of Vystar Corp. (“Vystar”)...
12 déc. 2025 08h42 HE | Source: Cytokinetics, Incorporated

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the...
23 oct. 2025 03h00 HE | Source: Vantage Hemp Co.

Vantage Hemp Co. Strengthens Global Footprint with Initiation of European Regulatory Filings

Greeley, Colorado, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Vantage Hemp Co. (“Vantage” or “the Company”), a globally accredited cannabinoid manufacturer, has initiated the submission process for its...
30 sept. 2025 15h30 HE | Source: Custom Market Insights

[Latest] Global HEOR Services Market Size/Share Worth USD 8.5 Billion by 2034 at a 13.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Health Economics and Outcomes Research HEOR Services Market Size, Trends and...

Page suivante